



## Restrictions on Transactions in Orexigen Therapeutics Inc. (OREXQ) on Cboe and C2 Exchanges

### **Overview**

Effective April 4, 2018, Orexigen Therapeutics Inc. (OREXQ) was delisted from the NASD. Therefore, trading in OREXQ options will be subject to restrictions pursuant to Cboe Options Rule 5.4. In addition, transactions in contravention of this restriction may be subject to nullification pursuant to Cboe Options Rule 6.25.

There are no restrictions in place with respect to the exercise of OREXQ options.

### **Additional Information**

Please contact the Cboe Operations Support Center (“OSC”) or Regulatory Interps. with any questions.

#### **Cboe Operations Support Center**

312.786.7351

[marketservices@cboe.com](mailto:marketservices@cboe.com)

#### **Regulatory Interps.**

312.786.8141

[reginterps@cboe.com](mailto:reginterps@cboe.com)